When politicians promise cheaper medicines, the mechanism matters more than the slogan: Medicaid’s “most-favored-nation” approach can lower net prices for select drugs at scale, but the size and staying power of the savings turn on how the benchmark is defined, which drugs are covered, and what portion of the already-discounted Medicaid market is actually exposed to new, deeper rebates.
The Short Version
- President Trump’s team announced a nationwide Medicaid model extending most-favored-nation (MFN) pricing to all states, D.C., and Puerto Rico, backed by a White House estimate of $64.3 billion in 10‑year savings.
- Mechanically, MFN ties U.S. net prices for targeted drugs to the lowest (or near-lowest) net prices in a peer-country basket — a form of international reference pricing.
- Skeptics argue Medicaid already secures steep rebates; the incremental savings could be modest and will vary by drug and state mix.
- The strongest evidence supports meaningful savings on specific, high-spend drugs with weaker baseline rebates; sweeping national totals are plausible but not yet independently verifiable.
What the administration put on the table — and why it matters
The administration’s claim is straightforward: extend MFN-linked pricing to Medicaid in every state and capture large, taxpayer savings without reducing coverage. The White House framed the initiative as universal in scope — all 50 states plus D.C. and Puerto Rico — and attached a concrete fiscal yardstick: $64.3 billion over a decade in lower Medicaid drug costs, attributed to analysis by the Council of Economic Advisers. The political appeal is obvious; Medicaid is a large, jointly financed program, so even moderate unit-price reductions echo through state and federal budgets. On the facts presented, the program’s breadth and the savings estimate are the centerpiece of the case.
At a mechanical level, MFN-style models alter the reservation price in negotiations by indexing net Medicaid prices for targeted drugs to an external benchmark — typically the lowest realized net price among a set of wealthy peer countries, sometimes adjusted for purchasing power. That architecture can meaningfully compress net prices when U.S. purchasers historically paid a premium relative to those peers, especially for specialty and biologic products with outsized budget impact.
How MFN interacts with Medicaid’s existing rebate machinery
Medicaid does not buy drugs the way commercial plans do; it is anchored by a statutory rebate floor, supplemental rebates negotiated by states, and “best price” provisions that automatically ratchet up rebates if a manufacturer gives anyone a better deal. MFN overlays that framework by forcing the manufacturer’s net Medicaid price toward an international reference. Where the existing net Medicaid price is already close to — or below — the MFN comparator, little changes. Where the gap is wide, the model compels deeper net concessions via larger supplemental rebates or MFN-linked price terms.
This explains the expected heterogeneity in savings. Analyses of MFN concepts generally find significant potential on selected high-spend agents, and modest gains where Medicaid already extracts steep rebates. Put differently: the tail of expensive, less-rebated drugs drives the economics; the bulk of low- to medium-spend, already‑discounted products does not. That is consistent with the broader health‑economics literature on international reference pricing and payer leverage in markets with concentrated spend on a few blockbuster categories.
The strongest points of agreement — and where the real disagreement lives
Two claims are well supported. First, the administration positioned the model as national in scope; multiple reports and official statements describe participation by all 50 states, D.C., and Puerto Rico. Second, the policy’s intent is to anchor Medicaid prices to peer-country net prices — the textbook MFN idea applied to a public program. Those premises are not seriously contested in the record.
Disagreement concentrates on magnitude and verification. The White House’s $64.3 billion 10‑year savings figure is consequential but, by design, rests on internal modeling. Independent analysts caution that Medicaid already secures substantial discounts and represents roughly a tenth of U.S. drug spending; therefore, the incremental savings ceiling is lower than in Medicare or commercial markets. That logic is sound and empirically grounded, and it tempers expectations about sweeping, across-the-board reductions. It does not negate savings; it right-sizes them.
What an MFN benchmark can actually capture
MFN works when three conditions align: the comparator basket features genuinely lower net prices; the targeted drugs account for a large share of Medicaid spend; and the policy design transmits the lower benchmark into enforceable net prices without unintended spillovers that manufacturers can exploit. In practice, the first and third conditions are the fulcrum. A poorly curated basket — one dominated by countries whose “net” prices are inflated by confidential side deals — blunts the savings. A clear, enforceable transmission mechanism — via contract terms, best-price linkages, or model-specific rebates — amplifies it.
Experience from analogous reference pricing efforts suggests mixed but meaningful effects. Targeted MFN-style approaches tend to yield noticeable savings on a finite set of top-spend drugs; broad, headline figures depend on how many molecules fall under the rule and whether those molecules are the ones driving trend. That is precisely why independent researchers often report ranges rather than point estimates and urge caution with single-number projections that precede public release of model specifications.
HUGE: The Trump Admin is extending the incredible benefits of Most-Favored-Nation drug pricing to ALL state Medicaid programs across the country.
This will save states BILLIONS of dollars as @POTUS continues to usher in the biggest price reduction in prescription drugs. pic.twitter.com/EZiGefWuIN
— Maga Nation (@tmoneJs) September 18, 2026
Patients, states, and manufacturers: distribution of gains and frictions
In Medicaid, “savings” principally accrue to taxpayers — split between state and federal treasuries — because statutory cost sharing keeps most beneficiaries’ out-of-pocket exposure low. For states managing tight budgets, this is the point; lower net prices create room for other services or eligibility protection in downturns. For manufacturers, MFN compresses U.S. net prices and can complicate global pricing strategies if best-price rules propagate the U.S. concession elsewhere. Industry arguments that MFN “just transfers money to government” miss the Medicaid design reality: the program’s financial architecture is supposed to buy more coverage and services per public dollar. The relevant test is whether access is preserved and adherence improves as budgets stretch — not whether list prices stay cosmetically high.
How to judge the $64.3 billion claim
An internally modeled estimate is neither proof nor puffery by default; its credibility rides on scope, basket, and enforcement details that determine how much of Medicaid’s drug spend is actually repriced. The assertion that every state, D.C., and Puerto Rico are in the model is clear; the MFN intent is consistent with longstanding policy debates; and the political incentives to tout a large number are obvious. Independent confirmation of the exact decade‑long total will require transparent model specifications and drug‑level impact data over time. Until then, the conservative, evidence‑based posture is this: national MFN scaffolding for Medicaid is likely to generate real savings concentrated in a subset of high‑spend drugs, with aggregate totals that could be large but will almost certainly fall below maximalist readings of headline claims.
What to watch in implementation
Four levers will determine outcomes. First, the comparator design: which countries, what definition of “net,” and how often the benchmark refreshes. Second, the drug inclusion rules: are top‑spend biologics and specialty drugs fully in scope, or are carve‑outs diluting impact. Third, interaction with best‑price and supplemental rebates: do MFN terms translate cleanly into higher mandatory or negotiated rebates, or do they create perverse incentives. Fourth, state uptake in practice: national participation can still mask variability in how aggressively states negotiate and operationalize MFN‑linked rebates.
Get those right and MFN becomes more than a press release; it becomes a durable procurement tool. Get them wrong and the market adapts, savings erode, and the promise shrinks to isolated wins. The structure — not the sound bite — will decide which path Medicaid takes.
Sources:
wftv.com, rmb.reuters.com, whitehouse.gov, rollingout.com